Sanofi bucks unit-sale trend with plan to unload $7B worth of older products

Sanofi CEO Chris Viehbacher

While other companies are hiving off large pieces of their operations to get fit and focused, Sanofi ($SNY) has decided to simply clean out its closet. By selling off a number of older products, it can make room for the kind of bolt-on deals that CEO Chris Viehbacher said on Tuesday interest him. Report

Suggested Articles

Dupixent has been posting strong sales growth for Sanofi, and now the drugmaker has a third FDA indication to keep the momentum going.

Acadia Pharmaceuticals is taking Parkinson’s disease education on the road in a partnership with the Michael J. Fox Foundation.

AbbVie continues its long-running aggressive TV ad push for Humira last month, while Gilead Sciences takes two spots in the top 10 tally from iSpot.